Arbutus Biopharma Corp (ABUS) - Total Assets
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) holds total assets worth $274.02 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Arbutus Biopharma Corp (ABUS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Arbutus Biopharma Corp - Total Assets Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's total assets have evolved over time, based on quarterly financial data. See ABUS stock price for real-time trading data and today's change.
Arbutus Biopharma Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Arbutus Biopharma Corp's total assets of $274.02 Million consist of 99.8% current assets and 0.2% non-current assets. Explore working capital position of Arbutus Biopharma Corp to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.0% |
| Accounts Receivable | $1.75 Million | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arbutus Biopharma Corp's current assets represent 99.8% of total assets in 2025, an increase from 43.1% in 1998.
- Cash Position: Cash and equivalents constituted 19.0% of total assets in 2025, up from 5.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Arbutus Biopharma Corp Competitors by Total Assets
Key competitors of Arbutus Biopharma Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Biohaven Ltd.
NYSE:BHVN
|
USA | $466.41 Million |
|
Galapagos NV
F:GXEA
|
Germany | €3.37 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Arbutus Biopharma Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 81.42 | 20.53 | 12.51 |
| Quick Ratio | 81.42 | 20.53 | 12.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $270.52 Million | $98.10 Million | $116.42 Million |
Arbutus Biopharma Corp - Advanced Valuation Insights
This section examines the relationship between Arbutus Biopharma Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 9.82 |
| Asset Growth Rate (YoY) | -28.2% |
| Total Assets | $94.62 Million |
| Market Capitalization | $929.12 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Arbutus Biopharma Corp's assets at a significant premium (9.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Arbutus Biopharma Corp's assets decreased by 28.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual total assets of Arbutus Biopharma Corp from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $94.62 Million | -28.16% |
| 2024-12-31 | $131.71 Million | -8.79% |
| 2023-12-31 | $144.40 Million | -26.11% |
| 2022-12-31 | $195.42 Million | -4.43% |
| 2021-12-31 | $204.49 Million | +49.17% |
| 2020-12-31 | $137.08 Million | +29.89% |
| 2019-12-31 | $105.53 Million | -53.69% |
| 2018-12-31 | $227.91 Million | -3.92% |
| 2017-12-31 | $237.20 Million | -14.03% |
| 2016-12-31 | $275.90 Million | -61.27% |
| 2015-12-31 | $712.29 Million | +502.62% |
| 2014-12-31 | $118.20 Million | +64.82% |
| 2013-12-31 | $71.72 Million | +36.34% |
| 2012-12-31 | $52.60 Million | +283.84% |
| 2011-12-31 | $13.70 Million | -34.80% |
| 2010-12-31 | $21.02 Million | -49.89% |
| 2009-12-31 | $41.95 Million | -0.93% |
| 2008-12-31 | $42.34 Million | +70.50% |
| 2007-12-31 | $24.83 Million | +311.53% |
| 2006-12-31 | $6.03 Million | -67.37% |
| 2005-12-31 | $18.50 Million | -55.00% |
| 2004-12-31 | $41.10 Million | -18.99% |
| 2003-12-31 | $50.73 Million | -4.67% |
| 2002-12-31 | $53.22 Million | -21.28% |
| 2001-12-31 | $67.60 Million | +107.86% |
| 2000-12-31 | $32.52 Million | +12.94% |
| 1999-12-31 | $28.80 Million | +81.88% |
| 1998-12-31 | $15.83 Million | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more